UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 29, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson | --- | --- | |---------------------------------------------------------------------|------------------------------ ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been nearly a year since my last Johnson & Johnson (NYSE: JNJ ) “J&J” article, where I highlighted their Q3 2023 earnings that beat the Street’s projections with $21.4B in revenue, which was up 6.8% year-over-year. At that time, it looked as if th ...

On Oct. 15, J&J (JNJ) announced strong third-quarter results, beating estimates for both earnings and sales. The Innovative Medicine segment outperformed expectations. However, the MedTech segment underperformed due to continued headwinds in Asia-Pacific markets like China.Sales in the Innovative Medicine segment rose 4.9% year over year to $14.58 billion. Higher sales of key products such as Darzalex, Tremfya, Uptravi, Opsumit and Erleada drove the segment’s growth. New drugs like Carvykti, Tecvayli and Sp ...

Johnson & Johnson (JNJ) infused positive optimism for the broader healthcare sector after posting solid third-quarter 2024 earnings on Oct. 15. The world's biggest healthcare products maker continued with its long streak of earnings beat and also beat revenue estimates. Impressed with the earnings results, a few analysts raised their target price on the stock.Given this, investors should tap the company’s growth prospects through ETFs with the largest allocation to this diversified drug maker. These include ...

Johnson & Johnson's Tom Aelbrecht, N-VA's Jan Jambon, Flemish Minister for Welfare and Culture ... [+] Caroline Gennez, Deputy department head of the nursing department Siska Van den Bergh, ZAS president Els van Doesburg and ZAS-CEO Willeke Dijkhoffz pictured during the construction start of the new front building of ZAS Palfijn hospital on Wednesday 02 October 2024, in Antwerp. BELGA PHOTO WARD VANDAEL (Photo by WARD VANDAEL / BELGA MAG / Belga via AFP) (Photo by WARD VANDAEL/BELGA MAG/AFP via Getty Images ...

Johnson & Johnson's latest financial checkup shows it's still in excellent health.Johnson & Johnson (JNJ 0.11%) recently declared its latest dividend. The healthcare giant is making a $1.24 per share quarterly payment in December. While that's flat from last quarter, the dividend is up 4.2% from last year's level. This year marked the company's 62nd consecutive annual dividend increase, keeping it in the elite class of Dividend Kings, companies with 50 or more years of dividend growth. The healthcare compan ...

Johnson & Johnson TodayJNJJohnson & Johnson$164.14 +2.53 (+1.57%) 52-Week Range$143.13▼$168.85Dividend Yield3.02%P/E Ratio10.25Price Target$174.31Add to WatchlistJohnson & Johnson’s NYSE: JNJ stock price advance has been reinvigorated. The stock price rally stalled a few years ago due to the COVID-19 bubble bursting and the divestiture of Kenvue NYSE: KVUE, but those days are behind, and business growth is still ahead. Today, Johnson & Johnson is a buy because its value, yield, and growth outlook provide a ...

Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024.The healthcare sector's latest quarterly-earnings parade kicked off on Tuesday with a report from Johnson & Johnson (JNJ 1.55%) that was somewhat mixed. As is often the case, the purveyor of pharmaceuticals and medical technology exceeded Wall Street estimates on the top and bottom lines.The average analyst following J&J expected the company to earn an adjusted $2.21 per share, but it reported a muc ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Johnson & Johnson (NYSE:JNJ) Q3 2024 Earnings Conference Call October 15, 2024 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman & Chief Executive Officer Joe Wolk - Executive Vice President, Chief Financial Officer Erik Haas - Head, Worldwide Litigation Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech Jennifer Taubert - Executive Vice President, Worldwide Chairman, Innovative Medicine John Reed - Executive Vice President, Innovativ ...